Onena Medicines

Onena Medicines AG is a Stanford University spin-out biotechnology company based in Switzerland that creates revolutionary AI-optimized medicines to deliver hope where it’s needed most. Onena´s growing pipeline of antibody programs targets a class of powerful secreted growth factors called Dual SMAD Inhibiting Proteins (DSIPs), which are needed for diseased cells to grow and mature. Neutralizing DSIPs has the potential to impact major problems in human health, ranging from cancer to obesity. Onena is the world´s first company to develop a computer vision-based system to design antibody medicines from scratch in silico.

We have two main competitive advantages. First, our growing first-in-class pipeline targets a class of novel powerful secreted growth factors called Dual SMAD Inhibiting Proteins (DSIPs), which we discovered are necessary for diseased cells to grow and mature. Our lead program, OMED-1, has demonstrated proof-of-concept in vivo efficacy in breast, brain, and colorectal cancers already. Second, we are the only company in the world that is developing a computer vision-based generative AI antibody discovery platform (NVIDIA took notice last year).